Fig. 6

Pretreatment with LPS followed by CA140 treatment decreased ERK signaling in LPS-stimulated BV2 cells. a–c BV2 microglial cells were pretreated with LPS (1 μg/mL) or PBS for 45 min, followed by treatment with vehicle (1% DMSO) or CA140 (10 μM) for 45 min and western blotting with anti-p-AKT and anti-AKT antibodies (p-AKT and AKT; con, n = 5; LPS, n = 5; LPS + CA140, n = 5). d–f BV2 cells were pretreated with LPS (1 μg/ml) or PBS for 45 min, followed by treatment with vehicle (1% DMSO) or CA140 (10 μM) for 45 min and western blotting with anti-p-ERK and anti-ERK antibodies (p-ERK and ERK; con, n = 6; LPS, n = 6; LPS + CA140, n = 6). g–i BV2 microglial cells were pretreated with LPS (1 μg/mL) or PBS for 30 min, followed by treatment with an ERK inhibitor (PD98059, 10 μM) or vehicle (1% DMSO) for 30 min and finally CA140 (10 μM) or vehicle (1% DMSO) for 5 h. Total RNA was then isolated, and IL-1β or COX-2 mRNA levels were measured by RT-PCR (COX-2 and IL-1β: con, n = 4; LPS, n = 4; LPS + CA140, n = 4). *p < 0.05, **p < 0.001, ***p < 0.0001